» Articles » PMID: 34455741

[Unrelated Cord Blood Stem Cell Transplantation for High-risk/refractory Childhood Acute Myeloid Leukemia: a Clinical Analysis of 160 Cases]

Overview
Specialty Hematology
Date 2021 Aug 29
PMID 34455741
Authors
Affiliations
Soon will be listed here.
Abstract

To retrospectively analyze the clinical outcomes of single unrelated cord blood transplantation (UCBT) in children with high risk and refractory acute myeloid leukemia (AML) . Between June 2008 and December 2018, a total of 160 consecutive pediatric patients with AML received single UCBT (excluding acute promyelocytic leukemia) . Myeloablative conditioning (MAC) regimen were applied. All patients received a combination of cyclosporine A (CsA) and mycophenolate mofetil (MMF) for the prophylaxis of graft -versus- host disease (GVHD) . The cumulative incidence of neutrophil cells engraftment at day +42 and platelet recovery at day +120 was 95.0% (95% 90.0%-97.5%) at a median of 16 days after transplantation (range, 11-38 days) and 85.5% (95% 83.3%-93.4%) with a median time to recovery of 35 days (range, 13-158) , respectively. Incidence of grades Ⅱ-Ⅳ and Ⅲ-Ⅳ acute GVHD and chronic GVHD were 37.3% (95%CI 29.3%-45.2%) , 27.3% (95% 20.0%-35.0%) and 22.4% (95% 15.5%-28.7%) , respectively. The transplant-related mortality (TRM) at 360 day was 13.1% (95% 8.4%-18.9%) . The 5-year cumulative incidence of relapse was 13.8% (95% 8.5%-20.3%) . The 5-year disease-free survival (DFS) and overall survival (OS) were 71.7% (95% 62.7%-77.8%) and 72.2% (95% 64.1%-78.7%) , respectively. The 5-year GVHD and relapse free survival (GRFS) was 56.1% (95% 46.1%-64.9%) . The 5-year cumulative recurrence rates of CR1, CR2, and NR groups were 5.3%, 19.9%, and 30.9% (=0.001) , and the 5-year OS rates were 79.9% (95% 70.3%-86.7%) , 71.1% (95% 50.4%-84.4%) and 52.9% (95% 33.0%-69.3%) ((2)=7.552, =0.020) , respectively. For pediatric patients with high risk and refractory AML, UCBT is a safe and effective treatment option, and it is favorable to improve the survival rate in CR1 stage.

References
1.
Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B . Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2015; 172(3):360-70. DOI: 10.1111/bjh.13802. View

2.
Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M . Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatr Blood Cancer. 2019; 66(10):e27875. DOI: 10.1002/pbc.27875. View

3.
Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View

4.
Wang X, Liu H, Li L, Geng L, Ding K, Liu X . Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies. Eur J Haematol. 2011; 88(1):39-45. DOI: 10.1111/j.1600-0609.2011.01709.x. View

5.
Isobe M, Konuma T, Kato S, Tanoue S, Mizusawa M, Oiwa-Monna M . Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019; 25(6):1187-1196. DOI: 10.1016/j.bbmt.2019.02.007. View